Emergency medicine updates : Atrial fibrillation with rapid ventricular response
Published by Elsevier Inc..
INTRODUCTION: Atrial fibrillation (AF) may lead to stroke, heart failure, and death. When AF occurs in the context of a rapid ventricular rate/response (RVR), this can lead to complications, including hypoperfusion and cardiac ischemia. Emergency physicians play a key role in the diagnosis and management of this dysrhythmia.
OBJECTIVE: This paper evaluates key evidence-based updates concerning AF with RVR for the emergency clinician.
DISCUSSION: Differentiating primary and secondary AF with RVR and evaluating hemodynamic stability are vital components of ED assessment and management. Troponin can assist in determining the risk of adverse outcomes, but universal troponin testing is not required in patients at low risk of acute coronary syndrome or coronary artery disease - especially patients with recurrent episodes of paroxysmal AF that are similar to their prior events. Emergent cardioversion is indicated in hemodynamically unstable patients. Rate or rhythm control should be pursued in hemodynamically stable patients. Elective cardioversion is a safe option for select patients and may reduce AF symptoms and risk of AF recurrence. Rate control using beta blockers or calcium channel blockers should be pursued in those with AF with RVR who do not undergo cardioversion. Anticoagulation is an important component of management, and several tools (e.g., CHA2DS2-VASc) are available to assist with this decision. Direct oral anticoagulants are the first-line medication class for anticoagulation. Disposition can be challenging, and several risk assessment tools (e.g., RED-AF, AFFORD, and the AFTER (complex, modified, and pragmatic) scores) are available to assist with disposition decisions.
CONCLUSION: An understanding of the recent updates in the literature concerning AF with RVR can assist emergency clinicians in the care of these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
The American journal of emergency medicine - 74(2023) vom: 15. Dez., Seite 57-64 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Long, Brit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Arrhythmia Agents |
|---|
| Anmerkungen: |
Date Completed 24.11.2023 Date Revised 24.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ajem.2023.09.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362727678 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362727678 | ||
| 003 | DE-627 | ||
| 005 | 20231226091837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ajem.2023.09.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362727678 | ||
| 035 | |a (NLM)37776840 | ||
| 035 | |a (PII)S0735-6757(23)00483-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Long, Brit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emergency medicine updates |b Atrial fibrillation with rapid ventricular response |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.11.2023 | ||
| 500 | |a Date Revised 24.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Elsevier Inc. | ||
| 520 | |a INTRODUCTION: Atrial fibrillation (AF) may lead to stroke, heart failure, and death. When AF occurs in the context of a rapid ventricular rate/response (RVR), this can lead to complications, including hypoperfusion and cardiac ischemia. Emergency physicians play a key role in the diagnosis and management of this dysrhythmia | ||
| 520 | |a OBJECTIVE: This paper evaluates key evidence-based updates concerning AF with RVR for the emergency clinician | ||
| 520 | |a DISCUSSION: Differentiating primary and secondary AF with RVR and evaluating hemodynamic stability are vital components of ED assessment and management. Troponin can assist in determining the risk of adverse outcomes, but universal troponin testing is not required in patients at low risk of acute coronary syndrome or coronary artery disease - especially patients with recurrent episodes of paroxysmal AF that are similar to their prior events. Emergent cardioversion is indicated in hemodynamically unstable patients. Rate or rhythm control should be pursued in hemodynamically stable patients. Elective cardioversion is a safe option for select patients and may reduce AF symptoms and risk of AF recurrence. Rate control using beta blockers or calcium channel blockers should be pursued in those with AF with RVR who do not undergo cardioversion. Anticoagulation is an important component of management, and several tools (e.g., CHA2DS2-VASc) are available to assist with this decision. Direct oral anticoagulants are the first-line medication class for anticoagulation. Disposition can be challenging, and several risk assessment tools (e.g., RED-AF, AFFORD, and the AFTER (complex, modified, and pragmatic) scores) are available to assist with disposition decisions | ||
| 520 | |a CONCLUSION: An understanding of the recent updates in the literature concerning AF with RVR can assist emergency clinicians in the care of these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anticoagulation | |
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Cardiovascular | |
| 650 | 4 | |a Cardioversion | |
| 650 | 4 | |a Dysrhythmia | |
| 650 | 4 | |a Rapid ventricular response | |
| 650 | 4 | |a Rate control | |
| 650 | 7 | |a Anti-Arrhythmia Agents |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Troponin |2 NLM | |
| 700 | 1 | |a Brady, William J |e verfasserin |4 aut | |
| 700 | 1 | |a Gottlieb, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of emergency medicine |d 1986 |g 74(2023) vom: 15. Dez., Seite 57-64 |w (DE-627)NLM01297868X |x 1532-8171 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2023 |g day:15 |g month:12 |g pages:57-64 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ajem.2023.09.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2023 |b 15 |c 12 |h 57-64 | ||